Schrödinger To Present New Preclinical Data From Its CDC7 Inhibitor Program At American Society Of Hematology 2022 Annual Meeting

Rhea-AI Summary

Schrödinger, Inc. (Nasdaq: SDGR) has announced the presentation of new preclinical data on its CDC7 inhibitor, SGR-2921, at the American Society of Hematology's 64th Annual Meeting in New Orleans from December 10-13, 2022. CDC7 is a cell cycle kinase crucial for DNA replication, and its inhibition serves as a promising approach for treating cancers like acute myeloid leukemia (AML). The company plans to initiate a Phase 1 trial of SGR-2921 for relapsed/refractory AML in the second half of 2023.

Positive

• Presentation of promising preclinical data on SGR-2921 at ASH meeting.
• Plans to initiate a Phase 1 trial for SGR-2921 in relapsed AML in 2023.

Negative

• None

NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that new preclinical data on its CDC7 inhibitor, SGR-2921, will be presented during a poster session at the American Society of Hematology (ASH) 64th Annual Meeting taking place virtually and in New Orleans, Louisiana, December 10-13, 2022.

CDC7 is a cell cycle kinase involved in DNA replication and is an important activator of replication stress and DNA damage responses. CDC7 inhibition is considered a promising therapeutic approach for the treatment of cancers, including acute myeloid leukemia (AML). Schrödinger is advancing SGR-2921 through investigational new drug (IND)-enabling studies with plans to initiate a Phase 1 trial in patients with relapsed/refractory acute myeloid leukemia (AML) in the second half of 2023.

Details of the poster presentation are as follows:

Title: Inhibition of CDC7 with SGR-2921 in AML models results in enhanced DNA damage and anti-leukemic activity as monotherapy and in combination with standard of care agents
Abstract number: 2653
Date & time: Sunday, December 11, 6:00 p.m. - 8:00 p.m. CDT
Location: Ernest N. Morial Convention Center, Hall D

About Schrödinger
Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance a portfolio of collaborative and proprietary programs to address unmet medical needs.

Founded in 1990, Schrödinger has approximately 800 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn and Instagram, or visit our blog, Extrapolations.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including but not limited to those statements regarding the potential advantages of our computational platform, the potential of CDC7 inhibition for the treatment of cancer, the therapeutic potential of SGR-2921, and the expected timing and design of our planned Phase 1 clinical trial of SGR-2921. Statements including words such as “aim,” "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," “goal,” "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," "would" and statements in the future tense are forward-looking statements. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Actual results may differ materially from those described in the forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond our control, including the uncertainties inherent in drug development, such as the conduct of research activities and the timing of and our ability to initiate and complete preclinical studies and clinical trials, uncertainties associated with the regulatory review of clinical trials and applications for marketing approvals, the ability to retain and hire key personnel and the direct and indirect impacts of the ongoing COVID-19 pandemic on our business and other risks detailed under the caption "Risk Factors" and elsewhere in our Securities and Exchange Commission filings and reports, including our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 4, 2022, as well as future filings and reports by us. Any forward-looking statements contained in this press release speak only as of the date hereof. Except as required by law, we undertake no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, changes in expectations or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005258/en/

Jaren Irene Madden (investors)

jaren.madden@schrodinger.com

617-286-6264

Tracy Lessor (media)

tracy.lessor@schrodinger.com

617-519-9827

Source: Schrödinger, Inc.

FAQ

What is Schrödinger's SGR-2921 and its purpose?

SGR-2921 is a CDC7 inhibitor aimed at treating cancers like acute myeloid leukemia (AML) through enhanced DNA damage and anti-leukemic activity.

When will the SGR-2921 Phase 1 trial start?

The Phase 1 trial for SGR-2921 is planned to begin in the second half of 2023.

What are the details of SGR-2921 presentation at the ASH meeting?

The presentation is titled 'Inhibition of CDC7 with SGR-2921 in AML models results in enhanced DNA damage and anti-leukemic activity as monotherapy and in combination with standard of care agents' and is scheduled for December 11, 2022.

Where is the American Society of Hematology meeting being held?

The ASH 64th Annual Meeting is taking place virtually and in New Orleans, Louisiana, from December 10-13, 2022.

What is CDC7's role in cancer treatment?

CDC7 is a cell cycle kinase that activates replication stress and DNA damage responses, making its inhibition a promising strategy for cancer therapies.